1. Introduction {#sec1}
===============

Of all modalities for the treatment of bladder outlet obstruction (BOO) caused by benign prostatic hyperplasia (BPH), open prostatectomy (OP) provides the highest probability of symptomatic improvement and the lowest failure rate.[@bib1] It is the true gold standard of BPH surgery with respect to outcome and durability. However, open surgery also has the highest perioperative morbidity. The 2003 American Urological Association guideline on the management of BPH reports a blood transfusion rate as high as 27%.[@bib2]

The disadvantages of OP include the need for long operating times and hospitalization. There may also be an increased potential for perioperative hemorrhage.

To reduce these disadvantages of OP and trim the remnant tissue after OP, we designed a novel suprapubic open prostatectomy (SOP) with transurethral adjustment of residual adenoma and bleeding (TURARAB) for larger sized prostates.

2. Methods {#sec2}
==========

2.1. Patients {#sec2.1}
-------------

Between March 2010 and April 2012, 29 patients with symptomatic BPH (\>100 g) were scheduled for SOP, and 20 patients with symptomatic BPH (\>100 g) were scheduled for SOP with TURARAB between June 2012 and March 2014. Exclusion criteria included previous transurethral surgery and conventional contraindications to OP or prostate cancer on biopsy. All patients gave their informed consent to the procedure. Prior to intervention, all patients were analyzed using preoperative complete blood count, blood chemistry, International Prostate Symptom Scores (IPSS), transrectal ultrasound of the prostate and maximum urinary flow rate (Qmax), postvoid residual urine (PVRU) volume, digital rectal examination, prostate specific antigen (PSA) measurement, and saturation (18 cores) TRUS-guided prostate biopsy if PSA was high (\>4 ng/mL). Postoperative outcome data were compared in the 1st month and 3rd month. All complications were recorded.

The patients were randomly subdivided into two groups. In Group I, each patient underwent SOP. In Group II, each patient underwent SOP with TURARAB.

2.2. Surgical technique {#sec2.2}
-----------------------

The procedure was performed under general anesthesia with the patient in a low lithotomy position. A lower midline incision was made from the umbilicus to the pubic symphysis. Vertical cystotomy was performed using electrocautery. With the use of electrocautery, cystotomy was extended cephalad and caudally to within 1 cm of the prostate-vesical junction. A "figure-of-eight" suture using a 2-0 Vicryl suture (ETHICON, Edinburgh, UK) was placed and tied at the most caudal position of the cystostomy to prevent further extension of the cystostomy incision. The bladder neck and prostate gland were well visualized. After marking the prostate, electrocautery created a circular incision in the mucosa of the prostate-vesical junction distal to the trigone starting from the posterior portion of the bladder neck to anterior portion. The plane between the prostatic adenoma and prostatic capsule was developed by index finger dissection. Prostatic adenoma, either as one unit or separate lobes, was removed from the prostatic fossa.

In Group I, hemostatic techniques in the prostatic fossa were performed.[@bib3] Briefly, discrete bleeding sites were controlled with electrocautery or 4-0 chromic suture (ETHICON, Edinburgh, UK) ligatures. In addition, a 0-chromic suture was used to place two "figure-of-eight" shaped sutures to advance the bladder mucosa into the prostatic fossa at the 5-o\'clock and 7 o\'clock positions at the prostate-vesical junction to ensure control of the main arterial supply to the prostate.

In Group II, four stitches at the 12 o\'clock, 3 o\'clock, 6 o\'clock, and 9 o\'clock positions by 2-0 Vicryl sutures (ETHICON, Edinburgh, UK) were used to mark the limitation between the bladder neck and prostatic fossa on TURRABC. To perform transurethral surgery for the residual adenoma and remnant fibrotic tissue ([Fig. 1](#fig1){ref-type="fig"}) and the severe bleeding points ([Fig. 2](#fig2){ref-type="fig"}), the cystostomy site was clamped with several Babcock clampers to prevent a leak of irrigation fluid from the cystostomy site. Any leakage of irrigation fluid was removed by suction tube. After transurethral surgery, the prostatic fossa and external sphincter were evaluated ([Fig. 3](#fig3){ref-type="fig"}). The cystotomy incision and skin were closed.

2.3. Statistical analysis {#sec2.3}
-------------------------

Baseline characteristics, perioperative data, Qmax, and PVRU of the two groups were compared by Mann--Whitney *U* test. A *P* value = 0.05 was considered significant. Operation time was measured from skin incision to skin closure.

3. Results {#sec3}
==========

3.1. Baseline characteristics {#sec3.1}
-----------------------------

There were no statistically significant differences in baseline characteristics between the two groups ([Table 1](#tbl1){ref-type="table"}).

3.2. Perioperative results {#sec3.2}
--------------------------

There was a marked decrease in operation time and perioperative bleeding in Group II compared with Group I ([Table 1](#tbl1){ref-type="table"}). Blood transfusion during the operation was not needed in Group II due to the easy control of arterial bleeding sites under the transurethral procedure. In Group II, the mean time for TURARAB was 23.5 min.

3.3. Outcome of voiding functions {#sec3.3}
---------------------------------

Postoperative voiding function was improved significantly in all groups ([Table 2](#tbl2){ref-type="table"}).

3.4. Complications {#sec3.4}
------------------

In Group I, blood transfusions were given to five patients due to severe bleeding. Three patients received recatheterisation due to clot retention. Wound dehiscence was seen in four patients. In Group II, no patient required transfusion and recatheterization. Wound dehiscence was present in one patient.

4. Discussion {#sec4}
=============

Even though the mortality of OP has decreased to a minimum,[@bib3; @bib4] mainly owing to the advent of better preoperative evaluation and anesthesia, with the therapeutic results obtained being excellent, OP has been displaced by transurethral resection of the prostate (TURP), mainly because of its invasiveness. However, despite considerable blood loss and a prolonged recovery, OP has been the traditional treatment of choice for extremely large prostates, over 100 g.[@bib5] In TURP, a larger prostate requires more resection time and has been associated with increased blood loss. Enucleating a large prostate can be much faster than removing it transurethrally. Compared with TURP, OP offers the advantages of lower retreatment rate and a more complete removal of the prostatic adenoma under direct vision. However, basic OP requires ligations of both the prostatic branch of the internal common iliac artery at the prostate-vesical junction and the intraprostatic capsular arterial braches. The ligations of intraprostatic capsular branches were very difficult and time consuming procedures because massive bleeding interrupts the process of finding the bleeding points. This is the main cause of blood loss and sometimes necessitates a blood transfusion. In addition, when excessive bleeding persists after traction of the ballooned urethral catheter, a cystoscopic inspection and fulguration of the prostatic fossa and bladder neck, or open reexploration should be considered.

Since 1994, holmium laser enucleation of the prostate (HoLEP) has been available for large prostates, but it is not easy to learn, requires morcellation, requires a prolonged operation time, and requires an expensive laser machine.[@bib6; @bib7] Compared with HoLEP, SOP with TURARAB also has an advantage of a reduced operating time. Moody and Lingeman[@bib8] reported their HoLEP experience. Mean preoperative prostate volume exceeded 100 g, and the operation time was 197 min. Morcellation consisted of approximately one-third of the total operating time (average 56/173 total operative minutes). Compared with our data, SOP with TURARAB has the advantage of a reduced operation time than HoLEP. Bipolar TURP has been recently introduced as a minimal invasive surgical method in the treatment of BPH. Coskuner et al.[@bib9] reported their experience for large prostates (\>100 g) with bipolar TURP. To the best of our knowledge, their study is known to be unprecedented for large prostates (\>100 g) with bipolar TURP. Mean preoperative prostate volume exceeded 116 g, and the operation time was 102 min. Compared with our data, operation time had no big difference. However, perioperative blood transfusion rate was 8.6% in bipolar TURP. SOP with TURARAB has the advantage of reduced perioperative blood transfusion rate than bipolar TURP. SOP with TURARAB has an advantage of reduced operation time and bleeding for patients with large prostates. But, an incision scar on the lower abdomen is a disadvantage of our novel method compared with HoLEP or bipolar TURP.

With the threshold for transfusion being a hemoglobin value of 10 g/dL, a transfusion rate of 8.2% was reported in a large study from Italy.[@bib10] In our study, in Group I, the transfusion rate was 12.5%. To reduce this kind of disadvantage of OP, we designed a novel SOP with TURARAB. After removal of the main adenoma, we converted the SOP to transurethral surgery. In this method, we were able to ascertain the exact sites of bleeding foci, remnant adenoma, and fibrotic tissue ([Figs. 1 and 2](#fig1 fig2){ref-type="fig"}). This reduced bleeding during the operation and perioperative hemorrhage, leading to a shortened operation time.

In the classic SOP, the prostatic fossa must be examined for discrete bleeding sites that can frequently be controlled with an electrocautery or 4-0 chromic suture ligatures. In addition, two "figure-of-eight" sutures of a 0-chromic are placed at the prostatovesical junction to prevent severe bleeding from the main arterial blood supplies after removing the prostate adenoma. SOP with TURARAB can save time in suturing bleeding sites. In our study, we appreciably reduced the time for bleeding control compared with SOP.

In addition, we were very surprised when we found many fibrotic tissues and remnant adenoma of the BPH at the enucleation site, especially the apical area of the prostatic fossa. TURARAB has advantages of being able to remove residual fibrotic tissue and remnant adenoma of BPH, to control severe bleeding and to create a good shape of the prostatic urethra ([Fig. 3](#fig3){ref-type="fig"}). In our study, improved voiding function was evident in both groups. But, long-term follow-up of these two groups may yield a different outcome.

To perform TURARAB, the cystostomy site was clamped with several Babcock clampers. The bladder was filled with Urosol, to provide a clear view of the prostatic urethra from the bladder neck. However, excessive pressure is exerted on the OP site of the prostatic urethra, which may cause transurethral resection syndrome. In our study, there was no case of transurethral resection syndrome because we used continuous irrigation during the operation.

In conclusion, even for large prostate glands, SOP with TURARAB appears to be an effective and safe operation to reduce operation time and bleeding for patients with large prostates who have to undergo OP rather than endoscopic surgery.
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![Perioperative endoscopic view of remnant adenomas (solid arrows).](gr1){#fig1}

![Perioperative endoscopic view of arterial bleeding in the prostatic fossa after open suprapubic prostatectomy.](gr2){#fig2}

![Perioperative endoscopic view of apical prostatic urethra after removal and trim of remnant adenoma by transurethral resection and cauterization.](gr3){#fig3}

###### 

Preoperative and perioperative characteristics of the groups.

                                        Group I (*n* = 29)[a)](#tbl1fna){ref-type="table-fn"}   Group II (*n* = 20)[b)](#tbl1fnb){ref-type="table-fn"}   *P*
  ------------------------------------- ------------------------------------------------------- -------------------------------------------------------- -------
  Age (y)                               73.1 ± 5.2                                              72.1 ± 4.2                                               0.359
  Total prostate volume (cc)            128.6 ± 17.4                                            125.1 ± 11.8                                             0.645
  Preoperative IPSS                     20.1 ± 5.0                                              19.2 ± 3.7                                               0.724
  Preoperative PSA                      14.9 ± 7.2                                              13.5 ± 6.7                                               0.154
  Preoperative Qmax (mL/s)              7.5 ± 3.2                                               6.1 ± 2.2                                                0.635
  Preoperative PVR volume               251 ± 90.9                                              245 ± 120.6                                              0.823
  Resected tissue (mL)                  85.2 ± 12.7                                             83.5 ± 23.5                                              0.072
  Operative time (min)                  123.1 ± 24.5                                            95.7 ± 14.9                                              0.015
  Hospitalization (d)                   12.1 ± 2.4                                              7.2 ± 1.2                                                0.032
  Intraoperative transfusion rate (%)   12.5                                                    0                                                        0.020
  Intraoperative loss of Hb (gm/dL)     3.3 ± 1.2                                               2.1 ± 0.9                                                0.043

IPSS, International Prostate Symptom Score; PSA, prostate specific antigen; PVR, postvoid residual urine; Qmax, maximum urinary flow rate.

Group I, suprapubic open prostatectomy.

Group II, suprapubic prostatectomy followed by transurethral adjustment of residual adenoma and bleeding.

###### 

Improvement of voiding function of the groups.

                                                    Preoperative   Postoperative   *P*                         
  ------------------------------------------------- -------------- --------------- ------------- ------------- ---------
  **Group I**[a)](#tbl2fna){ref-type="table-fn"}                                                               
                                                    Qmax           7.5 ± 3.5       23.1 ± 7.5    24.3 ± 3.7    \<0.001
                                                    PVRU volume    251 ± 90.9      50.2 ± 25.6   20.4 ± 12.6   \<0.001
                                                    IPSS           20.1 ± 5.0      14.3 ± 4.5    13.2 ± 3.4    0.037
  **Group II**[b)](#tbl2fnb){ref-type="table-fn"}                                                              
                                                    Qmax           6.1 ± 2.2       23.8 ± 12.7   25.3 ± 9.5    \<0.001
                                                    PVRU volume    245 ± 120.6     32.6 ± 13.4   21.2 ± 12.3   \<0.001
                                                    IPSS           19.2 ± 3.7      15.6 ± 5.2    11.5 ± 3.3    0.021

IPSS, International Prostate Symptom Score; PVRU, postvoid residual urine; Qmax, maximum urinary flow rate.

Group I, suprapubic open prostatectomy.

Group II, suprapubic prostatectomy followed by transurethral adjustment of residual adenoma and bleeding.
